Literature DB >> 15720262

Targeting microtubules for cancer chemotherapy.

Jun Zhou1, Paraskevi Giannakakou.   

Abstract

Chemical compounds that interfere with microtubules such as the vinca alkaloids and taxanes are important chemotherapeutic agents for the treatment of cancer. As our knowledge of microtubule-targeting drugs increases, we realize that the mechanism underlying the anti-cancer activity of these agents may mainly lie in their inhibitory effects on spindle microtubule dynamics, rather than in their effects on microtubule polymer mass. There is increasing evidence showing that even minor alteration of microtubule dynamics can engage the spindle checkpoint, arresting cell cycle progression at mitosis and eventually leading to apoptotic cell death. The effectiveness of microtubule-targeting drugs for cancer therapy has been impaired by various side effects, notably neurological and hematological toxicities. Drug resistance is another notorious factor that thwarts the effectiveness of these agents, as with many other cancer chemotherapeutics. Several new microtubule-targeting agents have shown potent activity against the proliferation of various cancer cells, including cells that display resistance to the existing microtubule-targeting drugs. Continued investigation of the mechanisms of action of microtubule-targeting drugs, development and discovery of new drugs, and exploring new treatment strategies that reduce side effects and circumvent drug resistance may provide more effective therapeutic options for cancer patients.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15720262     DOI: 10.2174/1568011053352569

Source DB:  PubMed          Journal:  Curr Med Chem Anticancer Agents        ISSN: 1568-0118


  118 in total

1.  Depth-sensing analysis of cytoskeleton organization based on AFM data.

Authors:  Katarzyna Pogoda; Justyna Jaczewska; Joanna Wiltowska-Zuber; Olesya Klymenko; Kazimierz Zuber; Maria Fornal; Małgorzata Lekka
Journal:  Eur Biophys J       Date:  2011-10-27       Impact factor: 1.733

2.  Bioactive substances with anti-neoplastic efficacy from marine invertebrates: Porifera and Coelenterata.

Authors:  Peter Sima; Vaclav Vetvicka
Journal:  World J Clin Oncol       Date:  2011-11-10

3.  Synthesis and biological evaluation of 2-amino-1-thiazolyl imidazoles as orally active anticancer agents.

Authors:  Wen-Tai Li; Der-Ren Hwang; Jen-Shin Song; Ching-Ping Chen; Tung-Wei Chen; Chi-Hung Lin; Jiunn-Jye Chuu; Tzu-Wen Lien; Tsu-An Hsu; Chen-Lung Huang; Huan-Yi Tseng; Chu-Chung Lin; Heng-Liang Lin; Chung-Ming Chang; Yu-Sheng Chao; Chiung-Tong Chen
Journal:  Invest New Drugs       Date:  2010-10-02       Impact factor: 3.850

4.  Characterization of the colchicine binding site on avian tubulin isotype betaVI.

Authors:  Shubhada Sharma; Barbara Poliks; Colby Chiauzzi; Rudravajhala Ravindra; Adam R Blanden; Susan Bane
Journal:  Biochemistry       Date:  2010-04-06       Impact factor: 3.162

5.  A novel agent, methylophiopogonanone B, promotes Rho activation and tubulin depolymerization.

Authors:  Yuko Ito; Akiko Kanamaru; Akihiro Tada
Journal:  Mol Cell Biochem       Date:  2006-10-07       Impact factor: 3.396

6.  Re-expression of LKB1 in LKB1-mutant EKVX cells leads to resistance to paclitaxel through the up-regulation of MDR1 expression.

Authors:  Kaisheng Mao; Fakeng Liu; Xiuju Liu; Fadlo R Khuri; Adam I Marcus; Mingsong Li; Wei Zhou
Journal:  Lung Cancer       Date:  2015-03-01       Impact factor: 5.705

7.  Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor.

Authors:  Gun-Hee Jang; Na-Yeon Kim; Michael Lee
Journal:  Mol Cell Biochem       Date:  2015-04-26       Impact factor: 3.396

8.  Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen.

Authors:  John McLaughlin; Vadim Markovtsov; Hui Li; Steve Wong; Marina Gelman; Yanhong Zhu; Christian Franci; D Wayne Lang; Erlina Pali; Joe Lasaga; Caroline Low; Feifei Zhao; Betty Chang; Tarikere L Gururaja; Weiduan Xu; Muhammad Baluom; David Sweeny; David Carroll; Arvinder Sran; Sambaiah Thota; Manjeet Parmer; Angela Romane; George Clemens; Elliott Grossbard; Kunbin Qu; Yonchu Jenkins; Taisei Kinoshita; Vanessa Taylor; Sacha J Holland; Ankush Argade; Rajinder Singh; Polly Pine; Donald G Payan; Yasumichi Hitoshi
Journal:  J Cancer Res Clin Oncol       Date:  2010-01       Impact factor: 4.553

9.  Relevance of an opioid, noscapine in reducing cystogeneses in rat experimental model of polycystic ovary syndrome.

Authors:  A Priyadarshani
Journal:  J Endocrinol Invest       Date:  2009-07-17       Impact factor: 4.256

10.  Growth inhibition and enhanced chemosensitivity induced by down-regulation of Aurora-A in human renal cell carcinoma Caki-2 cells using short hairpin RNA.

Authors:  Tomoaki Terakawa; Hideaki Miyake; Masafumi Kumano; Masato Fujisawa
Journal:  Oncol Lett       Date:  2011-04-28       Impact factor: 2.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.